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1762for multiple procedures (1,5).
Moreover, AF often recurs more
than 1 year after conventional
ablation (1,4) (deﬁned as late
AF [1]).
We hypothesized that the
elimination of patient-speciﬁc AF
sources (AF-sustaining substrates)
would provide more durable AF
elimination than conventional (tri-
gger) ablation, in which unablated
substrates can subsequently be en-gaged by reconnected pulmonary veins (PVs) (6,7) or
non-PV triggers (8–10). The CONFIRM (Conventional
Ablation for Atrial Fibrillation With or Without Focal
Impulse and Rotor Modulation) demonstrated that sub-
strates for persistent and paroxysmal AF include electrical
rotors (spiral waves) or focal sources in spatially reproduc-
ible locations for each patient that sustain AF. Targeted
ablation at AF sources alone in biatrial locations greatly
improved the 1-year to 2-year success of conventional
ablation in the CONFIRM trial (11), as shown by
independent laboratories (12,13).
We studied whether ablation guided by focal impulse and
rotor modulation (FIRM) prevented late AF recurrence and
thus maintained its relative efﬁcacy over conventional abla-
tion in an extended follow-up of the CONFIRM trial.Methods
Study design and enrollment. We studied the 92 unique
subjects in CONFIRM undergoing index FIRM-mapping
procedures, each referred for ablation of symptomatic AF
for standard indications at 3 centers (1). Subjects were 21
years of age, with AF despite 1 or more class I or III
antiarrhythmic drugs. The only exclusion to enrollment was
an inability or a refusal to provide written informed consent.
The population included paroxysmal AF (self-limiting
episodes), persistent AF (requiring drugs or electrical
shock to terminate or continuous AF for >7 days), and
longstanding persistent AF (continuous AF for more than
1 year) (1). Table 1 summarizes patient characteristics.
We analyzed AF recorded at multipolar biatrial catheters
using described computational methods using phase map-
ping of electrograms and repolarization and conduction
dynamics to map patient-speciﬁc sources (14). Consecutive
patients were prospectively enrolled under speciﬁc
institutional review board approval in a 2-arm 1:2 case-
cohort design for FIRM-guided ablation, after real-time
FIRM mapping had been developed, or the FIRM-
blinded group, in which sources were mapped ofﬂine. The
FIRM-guided group received targeted ablation of sources
followed by conventional ablation, while the FIRM-
blinded group received conventional ablation alone.
Electrophysiologic study. Electrophysiologic studies were
performed after discontinuing antiarrhythmic medicationsfor 5 half-lives, or >60 days for amiodarone (median 203
days). Catheters were advanced transvenously to the right
atrium and coronary sinus and trans-septally to the left
atrium. A 64-pole basket catheter (Constellation, Boston
Scientiﬁc Corporation, Natick, Massachusetts) was advanced
through an 8.5-F SL1 sheath (Daig Medical, Minnetonka,
Minnesota) to map AF in left atrium (n ¼ 92) and the right
atrium (n ¼ 61). Digital electroanatomic atrial shells were
created using NavX (St. Jude Medical, Minneapolis, Min-
nesota) or Carto (Biosense Webster, Diamond Bar, Califor-
nia) (15). Intravenous heparin was infused to achieve an
activated clotting time of >350 s. Unipolar and bipolar
atrial electrograms from the basket catheter were ﬁltered at
0.05 to 500 Hz and recorded at 1-kHz sampling frequency
for export from our electrophysiologic recording system
(Bard, Lowell, Massachusetts).
AF was observed in 88 patients (including all FIRM-
guided cases), including AF induced by rapid pacing
(n ¼ 26) or isoproterenol (n ¼ 2) when required. Induced
and spontaneous AF in a given patient have recently been
shown to have similar dominant frequency (16) and spatial
(14) patterns. The remaining 4 patients without induced
AF underwent conventional ablation in sinus rhythm in
routine fashion.
FIRM mapping of AF sources. FIRM mapping has been
described (11,14). Brieﬂy, AF was recorded using wide-
ﬁeld-of-view basket catheters then analyzed using a map-
ping system (RhythmView; Topera, Palo Alto, California)
using phase-based algorithms to project 3-dimensional maps
of AF propagation (an ‘activation trail’) onto grids.
AF (FIRM) maps were analyzed intraprocedurally to guide
ablation in FIRM-guided patients and post-procedurally in
FIRM-blinded patients. Electrical rotors (Fig. 1) were deﬁned
as phase-mapped rotation, while focal impulses showed
centrifugal activation from an origin, both with precession
(“wobble”) and complex surrounding breakdown that
obscure ﬁbrillatory sources on simple activation maps.
Rotors and focal impulses were considered AF sources
only if they lay in reproducible regions, with precession
(17), on repeated analysis for thousands of cycles.
Ablation approach. Radiofrequency energy was delivered
with a 3.5-mm-tip irrigated catheter (ThermoCool, Biosense
Webster) at 25 to 35 W or, in patients with heart failure, an
8-mm-tip catheter (Blazer, Boston Scientiﬁc Corporation) at
40 to 50 W, with a target temperature of 52C. Ablation
commenced with FIRM in FIRM-guided subjects. Each
lesion was applied for about 30 s to cover the approximately
2-cm2 area of phase-mapped AF source precession (17).
Remapping for rotor elimination was not possible in
CONFIRM, because early software took hours to process,
so that the endpoint was AF termination or 10 min of
energy delivery (typically <5 min), whichever came ﬁrst.
FIRM was repeated for 3 sources (11) guided by the
single FIRM map, followed by conventional ablation. In
more recent studies, FIRM maps are generated fast enough
to enable remapping to conﬁrm rotor elimination (13).
Table 1 Characteristics of Population
Characteristic
FIRM-Blind
(Conventional) FIRM-Guided p Value
Type of AF 65 27 0.336
Paroxysmal AF 32.3% (21) 22.2% (6)
Persistent AF 52.3% (34) 63.0% (17)
Long-standing persistent AF 15.4% (10) 14.8% (4)
Age (yrs) 61.2  8.7 63.0  8.3 0.362
Men/women 63/2 25/2 0.578
AF history (days) 1,090 (413–2,712) 1,753 (1,127–3,249) 0.056
LA diameter (mm) 44  7 50  8 <0.001
LV ejection fraction (%) 55  12 52  17 0.430
Prior ablations 20% (13) 22.2% (6) 0.811
Comorbid conditions
Hypertension 45/64 25/27 0.049
Diabetes 20/64 11/27 0.383
Body mass index (kg/m2) 32.2  5.7 33.5  6.1 0.324
Obstructive sleep apnea 28/63 21/27 0.007
Congestive heart failure 26/65 11/27 0.947
BNP (pg/ml) 199  179 169  131 0.518
GFR (ml/min) 77.1  19.9 70.0  17.7 0.156
Magnesium (mg/dl) 2 (1.9–2.2) 2 (1.9–2.2) 0.972
Values are % (n), mean  SD, or median (interquartile range). Statistical comparisons were performed using chi-square tests (for incidences of AF
type, hypertension, diabetes mellitus, and obstructive sleep apnea), the Student t test (for age, LA diameter, LV ejection fraction, body mass index,
and laboratory data), and the Fisher exact test (for sex).
AF ¼ atrial ﬁbrillation; BNP ¼ brain natriuretic peptide; FIRM ¼ focal impulse and rotor modulation; GFR ¼ glomerular ﬁltration rate; LA ¼ left
atrial; LV ¼ left ventricular.
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FIRM-guided patients and as sole therapy in FIRM-
blinded patients, was standardized to comprise wide-area
circumferential ablation of the left and right PV pairs,
with veriﬁcation of PV isolation (PVI) using a circular
mapping catheter (Lasso; Biosense Webster). In patients
with persistent AF, a left atrial (LA) roof line was also
performed. Clinically relevant atrial tachycardia was
ablated. If AF or atrial tachycardia persisted after the
completion of ablation, cardioversion was performed.
Postprocedure clinical management. Follow-up for
arrhythmia recurrence exceeded guidelines (1). In a 3-month
post-ablation “blanking period,” antiarrhythmic medications
were continued (except amiodarone), but repeat ablation was
not permitted. Subjects were evaluated for recurrence using
continuous implanted electrocardiographic monitors if
possible (85.2% [23 of 27] of FIRM-guided patients,
23.1% [15 of 65] of FIRM-blinded patients), using Reveal
XT (Medtronic, Minneapolis, Minnesota) after its U.S.
approval for AF monitoring (2009) or clinical pacemakers
or deﬁbrillators. Subjects without implanted devices
underwent external event monitoring quarterly and at
the time of symptoms for 2 years. After this time, we
followed such patients at least annually and also reviewed
ambulatory data from our electronic medical system reﬂecting
periodic electrocardiograms or ambulatory electrocardiograms
obtained for any clinic visit or hospitalization. In patients
with arrhythmia recurrence after the blanking period, repeat
ablation was offered per guidelines (1), and if performed,
detailed mapping was repeated if consent was granted.Study endpoints. The primary endpoint was freedom from
AF, deﬁned as <1% burden on continuous implanted
electrocardiographic monitors (recording 100% of the year)
(11) or AF of <30 s in duration on quarterly monitoring (1)
(recording <28 days or 7.7% of the year). Secondary efﬁcacy
measures included freedom from all atrial arrhythmias and
arrhythmia freedom after a single procedure. Follow-up
was facilitated by the comprehensive electronic medical
record system in this largely Veterans Affairs population,
and all patients lost to follow-up in the original
CONFIRM trial (11) were recaptured. Follow-up
continued for >3 years in all patients, with none lost to
follow-up, for a median of 890 days (interquartile range
[IQR]: 224 to 1,563 days) when censored at recurrence.
On-treatment analysis: did ablation pass through
sources? Electroanatomic and FIRM maps were analyzed
in each patient blinded to demographics or outcomes, as
described (11). Lesions were considered to pass through an
AF source if 5-mm lesion markers on NavX lay within
0.5 interelectrode spacing of the electrode marking the
rotor core or focal origin. We assigned “source ablation”
if 1 source was ablated, whether directly by FIRM-
guided ablation or coincidentally by anatomic lesion sets.
Assignments were performed independently by S.M.N.,
D.E.K., K.S., and J.M.M., and disputes were resolved by
consensus. We compared long-term efﬁcacy for patients in
“source ablation” and “non–source ablation” groups.
Statistical analysis. Continuous variables are summarized
with means and standard deviations and were compared
using independent-samples Student t tests if normally
Figure 1 Patient Tailored Mapping
(A) Persistent atrial ﬁbrillation (AF) despite extensive wide-area circumferential ablation (WACA) and roof line ablation. Focal impulse and rotor modulation (FIRM) mapping
proceeded as shown ﬂuoroscopically, using biatrial baskets, coronary sinus and ablation catheters, an implantable loop recorder, and an esophageal temperature probe. (B)
Detection of right atrial AF rotor, where FIRM eliminated AF with no other ablation. (C) At 852 days, incessant atrial tachycardia recurred and was ablated at the original roof line
site. Abl D; Abl P ¼ ablation catheter recordings; CS1–9 ¼ coronary sinus; CSd to CSp ¼ coronary sinus recordings (distal to proximal); ECG ¼ electrocardiogram; IVC ¼ inferior
vena cava; RA1, RA2 ¼ right atrial recordings; post LA ¼ posterior left atrial recordings; SVC ¼ superior vena cava; TV ¼ tricuspid valve.
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Otherwise, they are summarized with medians and quartiles
or ranges and were compared using Mann-Whitney U
tests. Nominal variables were compared using chi-square
tests or Fisher exact tests if expected cell frequencies
were <5. Long-term outcomes were assessed and reported
after a single procedure and after multiple procedures of the
same type (i.e., PVI to PVI or FIRM guided ablation to
FIRM guided ablation). Survival analyses were conducted
using the Cox proportional hazards model. Survival curves
were produced using the Kaplan-Meier method and
compared using log-rank tests. Crossover repeat procedures
(PVI at index procedure crossing over to FIRM guided
ablation) were censored from Kaplan-Meier analysis but are
described in the “Results” section. The proportionality
assumption was deemed satisﬁed on inspection of log-log
plots. Covariates were added to this model if there were
treatment group differences with p values <0.10. In
multivariate models, AF history was transformed to the
common log. A p value <0.05 was considered statistically
signiﬁcant.Results
Table 1 summarizes the characteristics of the study
population.
Stable localized sources for human AF. AF was observed
intraprocedurally in 88 of 92 patients, in whom FIRM
mapping revealed stable AF rotors or focal sources in 86
(97.7%) for 1.9  1.1 concurrent stable sources per patient
(median 2; IQR: 1 to 2), of which 67% lay in the left atrium
(1.3 0.9 per patient; median 1; IQR: 1 to 2) and 33% lay in
the right atrium (0.6 0.7 per patient;median 0; IQR: 0 to 1).
Long-term efﬁcacy. Figure 1 illustrates a patient with
recurrent arrhythmia after FIRM-guided ablation. At 890
days (IQR: 224 to 1,563 days), freedom from AF was
higher for FIRM-guided than conventional therapy
(77.8% [21 of 27] vs. 38.5% [25 of 65], p ¼ 0.001) after
1.2  0.4 procedures (median 1; IQR: 1 to 1). After a
single procedure alone, freedom from AF was also higher
for FIRM-guided than conventional therapy for patients
undergoing ﬁrst ablation (75.0% [15 of 20] vs. 30.2% [16
of 53], p < 0.001) and all patients (66.7% [18 of 27] vs.
Figure 2 Freedom From the Primary Endpoint
Freedom from the primary endpoint (atrial ﬁbrillation [AF]) for focal impulse and
rotor modulation (FIRM)–guided ablation (blue) and conventional ablation (red)
(p ¼ 0.003).
Figure 3
Freedom From the Secondary Endpoint
(All Atrial Arrhythmias)
Freedom from the secondary endpoint (all atrial arrhythmias) for focal impulse and
rotor modulation (FIRM)–guided ablation (blue) and conventional ablation (red)
(p ¼ 0.01).
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with p values (log-rank test) are illustrated in Figures 2 to 4.
At 890 days (IQR: 224 to 1,563 days), freedom from any
atrial tachyarrhythmias was also higher in FIRM-guided
than conventional cases after 1.2  0.4 procedures (70.4%
[19 of 27] vs. 36.9% [24 of 65], p ¼ 0.003) and after a single
procedure including typical cavotricuspid ﬂutter (55.6% [15
of 27] vs. 26.2% [17 of 65], p ¼ 0.001) and excluding typical
cavotricuspid ﬂutter (63.0% [17 of 27] vs. 26.2% [17 of 65],
p ¼ 0.001). Seven subjects (7.6%) remained on antiar-
rhythmic medications because of patient or physician pref-
erence (3 FIRM guided, 4 conventional).
Repeat procedures were performed in 28 patients (8 FIRM
guided, 20 conventional). Of FIRM patients with AF
recurrence, 3 had atrial tachycardia (2 cavotricuspid, 1 LA)
and were successfully ablated, while 5 AF recurrences were
treated by FIRM. Six patients (75.0%) were free of recurrence
at 950 days (IQR: 658 to 973 days). Of conventional ablation
patients, 12 had repeat PVI (before the availability of real-
time FIRM), of whom 6 (50.0%) were recurrence free at
1,435 days (IQR: 836 to 1,767 days) (PVI, then PVI). Eight
patients who initially underwent conventional ablation and
had AF recurrence crossed over to FIRM ablation (and were
excluded from multiprocedure Kaplan-Meier analysis), of
whom 6 (75.0%) remained AF free at 1,939 days (IQR: 1,109
to 2,120 days) (PVI, then FIRM-guided ablation).
On-treatment analysis. Examining only single-procedure
results, ablation in which lesions passed through the sites
of 1 rotor or focal source (either directly, on FIRM, or
coincidentally by anatomically placed lesions) was more
successful than ablation that missed all sources (Fig. 5)
(p values reﬂect log-rank tests). Direct ablation through a
source did not differ signiﬁcantly from coincidental ablation
of a source in this study (69.2% vs. 57.1%, p ¼ 0.36),
which may reﬂect patient numbers.
Multivariate predictors of outcomes. We studied the
impact on freedom from AF of FIRM-guided versus con-
ventional ablation and demographic factors that differed
between groups with p values <0.10 (from Table 1: presence
of hypertension and obstructive sleep apnea; LA diameter
and AF history as continuous variables). On multivariate
analysis, single-procedure long-term success was associated
with FIRM-guided ablation (p < 0.001) and inversely
with AF history (p ¼ 0.006), hypertension (p ¼ 0.014),
and LA diameter (p ¼ 0.010). Sleep apnea and other
clinical factors did not impact outcome when FIRM-guided
ablation was considered. Multiple-procedure long-term success
was associated with FIRM-guided ablation (p ¼ 0.003) and
trended inversely with LA diameter (p¼ 0.052).
Discussion
Elimination of patient-speciﬁc electrical rotor and focal
sources for AF signiﬁcantly reduced late recurrence of atrial
arrhythmias on rigorous >3-year follow-up compared with
trigger ablation alone. On multivariate analysis, FIRM-guided ablation predicted procedural success independently
of comorbidities that otherwise favor the progression of AF
substrates. These data strengthen the concept that ablation
of deﬁned patient-speciﬁc AF-sustaining mechanisms pre-
vents recurrent AF even if PVs reconnect or alternative
Figure 5
Cumulative Freedom From the Primary EndPoint (AF)
in Patients Based on Whether the Procedure Directly
or Coincidentally Ablated Rotors or Focal Sources or
Missed Rotors or Sources
Data show all cases (solid lines; p < 0.001) and those at ﬁrst ablation
(dashed lines; p < 0.001).
Figure 4
Single-Procedure Freedom From the Primary
EndPoint (AF) for FIRM-Guided Ablation and
Conventional Ablation
Data show all cases (solid lines; p ¼ 0.002) and those undergoing their ﬁrst ab-
lations (dashed lines; p ¼ 0.002). AF ¼ atrial ﬁbrillation; FIRM ¼ focal impulse and
rotor modulation.
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1766triggers become active, both of which are major causes of
recurrent AF after conventional ablation.
Ablating stable rotors and focal sources substantially
improves arrhythmia freedom. These data strengthen the
concept that stable localized sources represent important
AF-sustaining substrates for human AF after it is triggered,
from the CONFIRM trial (11) and independent groups
(12,13,18).
These data suggest that the success of FIRM-guided
ablation is attributable more to FIRM than to PVI. Over a
median follow-up period of >3 years, the single-procedure
success of conventional ablation was <40% (Fig. 4), while
FIRM-guided ablation produced 70% to 80% arrhythmia
freedom. The single-procedure success of conventionally
treated patients in this study is in line with results from
Weerasooriya et al. (4) (one-third persistent AF) and
the <40% to 50% 1-year to 2-year single-procedure success
from multicenter trials of paroxysmal AF (5,19,20). The
relatively small increment in success with multiple versus 1
procedure (Figs. 2 and 3 vs. Fig. 4) in both limbs reﬂects
fewer patients undergoing repeat procedures in this study
(median 1; IQR: 1 to 1; mean 1.2  0.4) than in prior
studies (e.g., median 2, mean about 1.8 in Weerasooriya
et al.). Finally, ablation was more successful if sources were
eliminated, as demonstrated by on-treatment analysis in
this report (Fig. 5) and prospectively by the elimination of
paroxysmal AF by FIRM-only ablation in the PRECISE-
PAF (Precise Rotor Elimination Without Concomitant
Pulmonary Vein Isolation for the Successful Elimination of
Paroxysmal Atrial Fibrillation) trial (21). Although direct
FIRM ablation appeared slightly better than coincidentalrotor ablation in this long-term analysis, as may be
expected, this was not statistically signiﬁcant, possibly
because of patient numbers.
Stable AF sources explain many observations that are
difﬁcult to reconcile by disorganized mechanisms (22),
including AF termination by targeted intervention at sites
identiﬁed a priori hours earlier (11,12,23,24), consistent
activation vectors in AF (25,26), stable sites of rapid AF
activity (27–31), and organized re-entry before AF (32).
While AF rotors are rarely seen simply by activation
mapping, due to precession and complex breakdown,
they have been reported using methods including phase
mapping, wavelet similarity (18), the inverse solution (33),
intraoperative mapping (26), and possibly other methods
(34). Future work should deﬁne how electrical (35),
structural (36), or neural (37) remodeling contributes to
the formation and localization of AF sources.
Rotor and source ablation prevents late AF recurrence.
Recurrence and late recurrence of AF, occurring within 3
to 12 months and >12 months post-ablation, respectively
(1), have unclear mechanisms. One hypothesis is that
PV reconnection often accounts for recurrence (1,6,7),
although, conversely, patients with reconnected PVs often
do not have recurrence (38,39). A second mechanism is
that non-PV triggers may dominate after PVI (8–10).
A third mechanism is that progressive electrical (35),
structural (36), or neural (37) remodeling may facilitate the
progression of new substrates.
These data support the concept that substrate ablation by
FIRM may prevent AF recurrence by rendering reconnected
PV or non-PV triggers impotent. It has been shown
that patients after FIRM-only ablation may initially show
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regress (21), a phenomenon also seen after ablation for
supraventricular tachycardia. These results open the
possibility that elimination of patient-speciﬁc AF substrates
may attenuate deleterious remodeling, even in patients with
clinical comorbidities associated with substrate progression,
such as hypertension and sleep apnea.
Efﬁcacy of FIRM-guided ablation across patient
populations. FIRM-guided ablation retained its efﬁcacy
advantage in all patient subgroups. FIRMwasmore successful
if performed as a ﬁrst rather than a redo procedure (Figs. 4
and 5), which may reﬂect signal degradation from prior
ablation, pro-arrhythmia from prior ablation (Fig. 1), or
a biological resistance to therapy in such patients.
Nonetheless, despite these issues, patients with previous
ablation still achieved excellent long-term outcomes with
FIRM-guided therapy. FIRM also retained efﬁcacy in
patients with comorbidities that typically confer worse
outcomes from PV ablation, such as obesity and sleep
apnea, which associate with a larger number of AF rotors
that may lie in locations readily targeted by FIRM but
missed by PV ablation (40).
Study limitations. The major limitation of CONFIRM is
that it was nonrandomized, although subjects were enrolled
consecutively and treated prospectively for pre-speciﬁed
endpoints. Differences between groups may have reduced
the relative beneﬁt of FIRM therapy. Compared with
conventionally treated patients, FIRM-guided patients in
this analysis had more persistent AF (77.8% vs. 67.7%), a
higher prevalence of implanted loop recorders to detect
recurrence (85.2% vs. 23.1%), and more co-morbidities.
Although multivariate analysis showed a beneﬁt of
FIRM-guided therapy, we accept that such analyses cannot
take into account all potential differences. The CONFIRM
protocol was not ideal for assessing atrial tachycardia
recurrence because, for example, the protocol did not
standardize cavotricuspid isthmus ablation (most atrial
tachycardia recurrences in FIRM-guided patients). Also,
current baskets are suboptimal to ensure contact, that may
improve with future designs.
Some of these limitations are balanced by the unique
strengths of CONFIRM: implanted devices in >80% of
active limb patients and the “captive audience” of the largely
Veterans Affairs population in whom the integrated electrical
medical record system enabled us to capture events even for
noncardiology ofﬁce visits and hospitalizations. The multi-
procedure success of conventional (and FIRM-guided)
ablation in this trial would have been higher if more pa-
tients had undergone repeat ablation, but because of patient
preference, the number of repeat ablations was small (mean
1.2  0.4). Multiprocedure success would also have been
higher if crossovers to FIRM-guided ablation had been
included (6 of 8 arrhythmia free). Statistically, the sample size
imposed limits on the ability to conduct multivariate-adjusted
analyses. We limited the number of covariates, but replicationin larger samples would be useful. Finally, although
CONFIRM predominantly recruited men, studies from other
groups have since validated its ﬁndings in women (12,13).
Conclusions
In this extended follow-up of the CONFIRM trial,
FIRM-guided ablation was more effective than conven-
tional ablation alone at preventing early and late
arrhythmia recurrences. By removing patient-speciﬁc AF
substrates, FIRM may prevent recurrent AF from
reconnected PVs or non-PV triggers. Future studies
should further deﬁne how ablation of patient-speciﬁc AF-
sustaining substrates alters the natural history of long-
term arrhythmia recurrence.
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